Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria toxoid + tetanus toxoid + acellular pertussis is a trivalent combination vaccine used for active immunization against diphtheria, tetanus, and pertussis. It is composed of inactivated toxins (toxoids) from *Corynebacterium diphtheriae* and *Clostridium tetani*, along with purified components of *Bordetella pertussis*. The acellular pertussis component typically includes pertussis toxoid (PT) and filamentous haemagglutinin (FHA), and may also contain pertactin (PRN) and fimbriae (FIM). There are two primary formulations: **DTaP**, which contains higher concentrations of antigens for the initial pediatric series in infants and children up to 6 years of age; and **Tdap** (or dTpa), which contains reduced amounts of diphtheria and pertussis antigens for booster doses in adolescents, adults, and pregnant women. The vaccine is typically adsorbed onto an aluminum-based adjuvant to enhance the immune response. Major developers and manufacturers include GSK, Sanofi, and Mitsubishi Tanabe Pharma.
- Brand names
- DAPTACELAdacelBoostrix
- Other names
- DTaPTdapdTpaadsorbed acellular diphtheria-tetanus-pertussis combined vaccineadsorbed acellular DTP combined vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)Fimbrial antigen type 3PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis.